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Abstract
Objective To compare the effects of free nicotine replacement therapy
or proactive telephone counselling in addition to standard smoking
cessation support offered through a telephone quitline.
Design Parallel group, 2×2 factorial, randomised controlled trial.
Setting National quitline, England.
Participants 2591 non-pregnant smokers aged 16 or more residing in
England who called the quitline between February 2009 and February
2010 and agreed to set a quit date: 648 were each randomised to
standard support, proactive support, or proactive support with nicotine
replacement therapy, and 647 were randomised to standard support
with nicotine replacement therapy.
Interventions Two interventions were offered in addition to standard
support: six weeks’ nicotine replacement therapy, provided free, and
proactive counselling sessions (repeat telephone calls from, and
interaction with, cessation advisors).
Main outcome measures The primary outcome was self reported
smoking cessation for six or more months after the quit date. The
secondary outcomewas cessation validated by exhaled carbonmonoxide
measured at six or more months.
Results At six months, 17.7% (n=229) of those offered nicotine
replacement therapy reported smoking cessation compared with 20.1%
(n=261) not offered such therapy (odds ratio 0.85, 95% confidence
interval 0.70 to 1.04), and 18.2% (n=236) offered proactive counselling
reported smoking cessation compared with 19.6% (n=254) offered
standard support (0.91, 0.75 to 1.11). Data validated by carbonmonoxide
readings changed the findings for nicotine replacement therapy only,
with smoking cessation validated in 6.6% (85/1295) of those offered
nicotine replacement therapy compared with 9.4% (122/1296) not offered
such therapy (0.67, 0.50 to 0.90).
Conclusions Offering free nicotine replacement therapy or additional
(proactive) counselling to standard helpline support had no additional
effect on smoking cessation.
Trial registration ClinicalTrials.gov NCT00775944.
Introduction
Smoking remains a massive public health problem, is the single
most important avoidable cause of morbidity, and is responsible
for an estimated 45 000 cancer related deaths and 110 000
hospital admissions annually in the United Kingdom.1 Smoking
prevalence is strongly associated with social disadvantage1 2
and is the largest cause of social health inequalities.2 Effective
smoking cessation interventions such as nicotine replacement
therapy,3 bupropion,4 varenicline,5 and behavioural support are
available in many countries.6-8 However, even in the United
Kingdom, where smokers can access these at little or no cost,9
many quit attempts are unsupported.10 Increasing the use of
effective support for smoking cessation should be a public health
priority. Telephone quitlines can support smokers who are
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motivated to quit.11 In one year, about 6% of Scottish smokers
(>80 000) contacted a national quitline and of these, 1.4% (1 in
5) stopped smoking.12
The impact of a quitline could be maximised by optimising the
delivery of effective interventions. Proactive telephone support
involves repeated telephone calls by counsellors and may be
more effective than reactive support in which support materials
but little or no counselling are provided (odds ratio for proactive
versus reactive support 1.41, 95% confidence interval 1.27 to
1.57).11 Some quitlines now also offer nicotine replacement
therapy,13 which can increase the number of smokers who call
quitlines and use of quitline support14; however, the ultimate
impact of this strategy on cessation rates remains unknown. A
randomised controlled trial in the United States15 found that
offering nicotine replacement therapy promoted cessation
irrespective of the intensity of accompanying support (odds
ratio for abstinence after offer of nicotine replacement therapy
2.04, 95% confidence interval 1.73 to 2.41) but the only other
study to investigate this was uncontrolled.16 In the United States,
support for smoking cessation, including nicotine replacement
therapy, is not freely available from nationally organised health
services. Therefore offering nicotine replacement therapy with
or without proactive support by way of a quitline might have
different effects in other countries, such as the United Kingdom,
where cessation support is subsidised or freely available. We
investigated the effectiveness of offering free nicotine
replacement therapy and different intensities of support, through
a quitline provided for smokers residing in England.
Methods
We carried out a four group (2×2), parallel, factorial randomised
controlled trial among callers to the English National Health
Service smoking helpline, which assists smokers who live in
England. Participants were initially randomised to four equal
sized treatment groups; one group received standard support
and three received standard support plus combinations of two
interventions. For analysis purposes, as is standard in factorial
trials, our intention was, in the absence of any interaction
between the two trialled interventions, to combine the four
treatment groups into two groups in receipt of interventions
being tested.
Screening and randomisation
As we aimed to replicate the standard practice of a helpline, we
offered enrolment to the trial to all smokers who contacted the
helpline (by telephone, internet, or interactive TV), wanted help
with cessation, and were willing to accept standard care by the
quitline. Between 3 February 2009 and 13 January 2010, we
gave all non-pregnant regular smokers who were aged 16 or
more and agreed to set a quit date after four days but within
four weeks, verbal and written information about the trial and
invited them to join. The eligibility criteria were integrated into
the quitline clinical information system such that counsellors
were prompted to complete a template recording an offer of
trial entry to all callers that met the three criteria. Trained
advisors obtained consent; participants agreed to receiving
cessation counselling by telephone, follow-up for research
purposes, and potentially providing a sample of exhaled air for
measurement of carbonmonoxide. Nicotine replacement therapy
was not specifically mentioned but participants were told that
if they entered the trial they would be offered one of four
combinations of evidence based smoking cessation support,
some of which were not usually available through the NHS
smoking helpline.
Advisors randomised participants using a computer generated
random number sequence integrated into the computer system,
which guided cessation counselling. To minimise withdrawals
among those who might be unhappy with their treatment
allocation, participants were sent detailed information sheets
after randomisation that gave only specific details about the
treatments to which they had been randomised.
Interventions
All participants received standard support and, in addition,
combinations of two interventions: intensive proactive
counselling with or without nicotine replacement therapy (see
supplementary figure for contacts between participants in the
trial arms and quitline).
Less intensive support (standard care)
After an initial enrolment call, for standard support, participants
were offered further support materials at particular times by
email, letter, or text message. They were free to opt out of such
contacts. Messages sent before the participants’ quit dates were
intended to boost motivation and aid preparation for their
cessation attempt; ones sent on the quit date wished the
participant “good luck,” and those sent soon after quit dates
were intended to increase motivation and help make the quit
attempt successful. Later messages inquired about success (one
month), dealt with maintaining abstinence (three months), and
congratulated the participant for attempting a quit attempt (six
months). Participants receiving standard support were also
offered proactive telephone contact and, if they accepted this,
were contacted (telephone, email, or text) one week before and
on the day of their quit dates and then at two days and three
weeks after, with brief motivational messages but not following
set templates. All participants were informed about how to
obtain effective cessation support, including nicotine
replacement therapy, from NHS sources.
Intervention 1: offer of free nicotine replacement
therapy
Participants were offered no cost vouchers for 21 days’ supply
of 15 mg/16 hr transdermal nicotine patches, which were
redeemed by a telephone call. To ensure safety, we did not offer
vouchers to participants whowere breast feeding, were pregnant,
were allergic to elastoplasts, or had a chronic skin conditions;
participants were asked to discuss any safety concerns about
nicotine replacement therapy with their doctor. When safety
concerns were lacking we offered a voucher, and on acceptance
the participant’s name, postal address, and unique identifier
were automatically sent to the public health pharmacy
department at NHS Greater Glasgow and Clyde. No further
paper or electronic documentation for vouchers was sent to
participants, and participants claimed their initial supply of
nicotine replacement therapy by telephoning the pharmacy
through a freephone number; a second 21 day supply could be
redeemed in the same way three weeks after the initial batch.
Participants were advised to re-contact the pharmacy if supplies
did not arrive.
Intervention 2: more intensive, more frequent
proactive counselling
Following the enrolment telephone call, we contacted
participants once before their quit dates (twice if quit dates were
more than three weeks after enrolment), on their quit dates, and
then 3, 7, 14, and 21 days after their quit dates. Call content was
more structured than with standard quitline support and, apart
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1696 doi: 10.1136/bmj.e1696 (Published 23 March 2012) Page 2 of 13
RESEARCH
from calls at seven and 14 days after quit, advisors were trained
to counsel callers using specific templates employing
motivational interviewing techniques that were appropriately
matched to the cessation process. Earlier calls concentrated on
preparation and later ones focused on remaining abstinent and
avoiding relapse (see the manual available at www.ukctcs.org/
ukctcs/research/featuredprojects/portsss.aspx):
• Two weeks before the quit date we discussed the structure
of the programme and drug use and confirmed (or
renegotiated) the intention to quit
• Two days before the quit date we confirmed (or
renegotiated) the quit date and enhanced the motivation or
confidence for cessation
• Three days after the quit date we assessed progress,
including the impact of withdrawal symptoms, and
discussed strategies for avoiding relapse or ameliorating
withdrawal
• At 21 days after the quit date we discussed withdrawal,
avoiding relapse, motivation, and self confidence.
The telephone calls scheduled for seven and 14 days after quit
did not follow a set template, but advisors were encouraged to
use their skills to respond to participants’ needs. At the end of
each call, advisors arranged mutually convenient times to
telephone participants; the pattern and frequency of calls were
based on previously trialled schedules17 and the frequency of
face to face counselling already offered by the NHS. A manual
used to guide delivery of this intervention is available at www.
ukctcs.org/ukctcs/research/featuredprojects/portsss.aspx.
Staffing training and quality control
Advisors from two helpline centres (Glasgow and Brora,
Scotland) received 1.5 days training in the trial’s procedures
(2.5 days for those delivering more intensive proactive support).
Training in trial procedures involved familiarising advisors with
the enrolment and consent procedures and the rationale for the
trial. The additional day’s training for delivering more intensive,
proactive support included learning about patterns of smoking
and smoking prevalence, the addictive nature of nicotine, the
use of nicotine replacement and other drug therapies, developing
skills in reflective listening and other motivational interviewing
techniques, and gaining confidence in delivering additional
proactive calls using templates. (Training course materials are
available at www.ukctcs.org/ukctcs/research/featuredprojects/
portsss.aspx.) One author (AMcE) developed the behavioural
intervention and led training, assisted by helpline managers. To
practise skills gained in training sessions, advisors piloted
delivering the four template calls by phoning volunteers who
role played quitline callers while AMcE or helpline quality
assurance managers listened in to provide appropriate feedback.
The advisors’ knowledge was assessed by multiple choice
questions before and after the training sessions. Advisors with
low scores received extra training. After initial instruction and
while the trial was recruiting, the helpline’s internal quality
management processes, augmented by site visits by AMcE,
sustained the integrity of the intervention for the recruitment
period. AMcE visited the helpline headquarters twice and
listened in on calls together with a helpline quality assurance
manager; the quality assurancemanager and advisors were given
feedback on the delivery of calls. Between visits from AMcE,
the quality assurance manager regularly monitored advisors’
calls to ensure that the intervention was consistently delivered
as intended. Training, assessment of advisor competence in
delivery of the intervention, and quality assurance processes
are specified in a detailed report available from www.ukctcs.
org/ukctcs/research/featuredprojects/portsss.aspx.
Quitline system to ensure call delivery
The quitline used an automated system to ensure that calls were
delivered. If participants could not be contacted at pre-arranged
times, the system prompted a repeat call after three hours, with
further attempts at three hour intervals until 9 pm on weekdays
and 6 pm at weekends. The scheduling of repeat calls was not
controlled by advisors; the system required that advisors made
at least three attempts to contact participants before their attempt
could be deemed unsuccessful, and where necessary quitline
staff had ethical approval for leaving messages on participants’
answering machines.
Data collection at baseline and through
pharmacy
Quitline advisors collected and entered baseline data. Questions
asked of participants and data entered were integrated into the
electronic clinical information system used by the advisors,
minimising any disruption caused by running the trial. Baseline
measures included birth date; sex; postcode; employment;
ethnicity; eligibility for free prescriptions; educational
attainment; number of smokers sharing home; previous
treatments for nicotine addiction; strength of nicotine addiction,
as measured by the heaviness of smoking index18; urges to
smoke19; quit attempts lastingmore than 24 hours in the previous
year; and health status, measured by EQ-5D.20 It was routine
practice to log telephone contacts between participants and the
helpline; for use as a process measure we extracted data on the
numbers of successfully completed calls. We also recorded the
numbers of participants who could not be offered free nicotine
replacement therapy, because of, for example, concerns about
safety. Subsequently the pharmacy logged the numbers of
participants who redeemed vouchers and were sent nicotine
replacement therapy, were sent a replacement supply because
the original had not arrived, and were sent a second three week
supply.
Data collection at follow-up
Researchers working for the market research company BMRB
Social Research and who were blind to treatment allocations,
collected follow-up data by telephone at one and six months
after quit dates. Researchers made up to 25 attempts to contact
participants on their preferred phone number; calls times were
varied and included evenings and weekends to give the
maximum opportunity to reach participants. Where initial calls
were to discontinued or incorrect phone lines, BMRB checked
numbers with the quitline and obtained more recent phone
numbers when available. Data relating to one month outcomes
could be used if collected within three weeks of this, and
outcome data at six months could be used if obtained within
four weeks of this time point. An automated call system
prompted BMRB staff to make repeated calls to participants.
At both times, they requested smoking status, use of smoking
cessation support (including trial nicotine replacement therapy),
and numbers of quit attempts made since the one agreed at
enrolment. At six months, the EQ-5D was repeated and up to
three attempts were made to visit participants who reported not
smoking since their quit dates to validate cessation by
measurement of exhaled carbon monoxide, using a cut point of
less than 10 ppm to represent not smoking (Russell standard).21
Participants who could not be contacted by telephone at six
months were sent a postal questionnaire to record compliance
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with the primary outcome; no attempt was made to validate
these respondents’ reports of cessation.
Outcomes
The primary outcome was self reported, prolonged abstinence
from the quit date to six months; lapses were permitted provided
no more than five cigarettes in total were smoked.21 Prolonged
abstinence between the quit date and one month was monitored
as a secondary outcome. Lapses were permitted as long as five
or fewer cigarettes in total were smoked during this period.
Other secondary outcomes included abstinence for at least seven
days, ascertained at one and six months after the quit date and
reported abstinence for at least three months and numbers of
unsuccessful quit attempts of more than 24 hours’ duration,
both ascertained at six months. We had planned to monitor
smoking status, recorded by quitline staff at three days after the
quit dates, but it proved unfeasible to routinely record these data
for all participants. This outcome was therefore not measured
in the trial and is not reported.
Statistical analysis
Assuming no interaction between interventions (offers of free
nicotine replacement therapy or proactive support) and a quit
rate of 8% in the group receiving standard support only (neither
intervention), we aimed to recruit 2574 participants, providing
90% power at a 5% significance level to detect an odds ratio of
1.5 for the effect of offering, in addition to standard support,
either free nicotine replacement therapy or proactive support.
In the event of an interaction being present, combining the four
treatment groups to form intervention groups would not be
appropriate so in this eventuality, we anticipated comparing the
four treatment groups but with substantially reduced power. For
the primary analysis we used an intention to treat approach,
with those lost to follow-up presumed to be smoking. In a
logistic regression model we found no interaction between the
effects of standard or more intensive support and the offer of
nicotine replacement therapy or no nicotine replacement therapy.
We used χ2 tests to compare, using a 5% significance level,
outcomes among all participants randomised to more intensive,
more proactive versus standard support and offer of nicotine
replacement therapy versus no offer. From the literature a priori
we identified age, sex, age of leaving full time education, and
heaviness of smoking index as important prognostic covariates,
and used multiple logistic regression to adjust for them.22 As
there was less than 5% data missing for each covariate, this
analysis was a complete case analysis and included participants
only with complete data on all covariates. Subsequently we
carried out a sensitivity analysis to determine the influence of
missing data on smoking status on the study conclusions, varying
the strength of association between smoking status and
“missingness” (that is, whether data are missing), and using
multiple imputation to allow for variation in individual sampling
and imputation.23 Finally, to establish whether the effect of each
treatment was similar for different socioeconomic groups, we
carried out a test for interaction between the index of multiple
deprivation and each treatment effect for the primary outcome.
An economic analysis was carried out but will be reported
elsewhere.
Results
During recruitment the helpline received 188 926 contacts. An
interest in cessation was expressed by 75 272 of these people
and 26 468 agreed to receive support materials and counselling.
Overall, 5355 smokers were eligible and invited to enrol in the
trial; 36 of 2627 who agreed did not complete randomisation
owing to technical difficulties and the remaining 2591
participants were randomised (figure⇓). Fifty six participants
withdrew consent to use their data but were included in an
intention to treat analysis, with their data analysed as for those
with missing outcome data. At six months, telephone contact
was made with 58.0% (n=1354) of smokers for whom up to
date contact details were available, and this was similar across
the four intervention groups (table 1⇓). Of the 1295 participants
randomised to the offer of nicotine replacement therapy, 185
(14.3%) either declined the voucher or could not be offered one,
leaving 1110 participants for whom a voucher was available.
Of these, 798 (71.9%) telephoned the pharmacy to redeem
vouchers and were sent at least one supply of nicotine
replacement therapy, 233 (21.0%) requested a second supply,
and 10 contacted the pharmacy about a missing supply.
Treatment groups were well balanced (table 2⇓). More women
than men enrolled and participants were predominantly white
(88.1%), with a median age of 38 and a mean index of multiple
deprivation score of 26.7, higher than the English national
average (21.6),24 indicating greater socioeconomic deprivation;
almost 70% were heavily or moderately heavily dependent
smokers, with 40% smoking within five minutes of waking.
At six months, 490 (18.9%) participants reported prolonged
abstinence from smoking since their quit date (469 by telephone
and 21 by questionnaire). Of these, 388 (79.2%) agreed to a
home visit for validation of carbon monoxide levels (the 21
questionnaire respondents were not asked to consent to
validation visits). Of the 255 (52.0%) who provided exhaled
carbonmonoxide samples, 207 (81.2%) readings confirmed self
reported abstinence. Table 1 presents these data by intervention
group. The interaction between the effects of levels of support
provided and whether or not nicotine replacement therapy was
offered was not significant on the primary outcome (P=0.65).
The trial findings are therefore summarised by intervention
groups rather than by treatment groups.
Tables 3⇓ and 4⇓ summarise outcomes in intervention groups
and show that neither offers of more intensive proactive
telephone support nor of nicotine replacement therapy
significantly increased rates of reported prolonged smoking
cessation at six months. In the proactive support group, 18.2%
(n=236) of participants reported cessation compared with 19.6%
(n=254) of those who did not receive proactive support (odds
ratio for cessation with proactive support 0.91, 95% confidence
interval 0.75 to 1.11). Overall, 17.7% (n=229) of smokers
offered nicotine replacement therapy and 20.1% (n=261) not
offered nicotine replacement therapy stopped smoking (odds
ratio for cessation with offer of nicotine replacement therapy
0.85, 0.70 to 1.04). Validated and non-validated abstinence rates
between those receiving standard care and those receiving more
intensive proactive support did not differ significantly for any
outcome, at either one month or six months. At six months,
compared with participants not offered nicotine replacement
therapy, those offered nicotine replacement therapy tended to
be less likely to report sustained abstinence from smoking for
all outcomes; however, no differences were apparent at one
month. Sensitivity analysis, varying the degree of association
between smoking status and missingness rather than assuming
all missing data to be from smokers, did not affect the study
results.
Table 5⇓ summarises the numbers of successful (answered)
telephone calls to participants, their reported use of nicotine
replacement therapy issued in the trial, and other non-trial
smoking cessation support. In total, 70.0% (555/798) of
participants who redeemed their vouchers recalled obtaining
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nicotine replacement therapy in this way at six months
afterwards, and 62.7% (500/798) reported using at least some
nicotine replacement therapy. Utilisation of non-trial smoking
cessation support seemed similar in the standard care and more
intensive proactive support groups. However, participants who
were not offered nicotine replacement therapy were more likely
to use such therapy prescribed by a health professional, or
varenicline, and to have attended an NHS Stop Smoking Service
than those who were offered the vouchers. The median number
of successfully connected outbound calls from the helpline to
participants in the more intensive proactive support group was
three (two in standard support group), which was substantially
less than the number of calls that were offered to smokers in
this group.
Discussion
Among smokers who were motivated enough to call the English
NHS Smoking Helpline, set a quit date, and accepted an offer
of support for smoking cessation, offering either additional free
nicotine replacement therapy or higher intensity proactive
telephone support did not increase quit rates over and above
those obtained using standard quitline care.
Strengths and limitations of the study
The trial achieved its a priori sample size and was powered to
detect odds ratios of 1.5 for either intervention, although no
effects of this magnitude were apparent. Only 58% of smokers
were contacted at six months and, in the intention to treat
analysis, all who could not be contacted were assumed to be
smoking. This conservative supposition could possibly mask
variation in actual smoking patterns at six months and we
explored this possibility by trying alternative associations
between missingness and smoking status. This analysis did not
change our findings; however, it remains possible that we failed
to detect a significant effect attributable to one or both
interventions because of other biases related to the low follow-up
rate. At one month, higher follow-up rates were, however,
attained (65.3%) and, even with these more complete data and
the higher overall quit rates at one month (40.1%), no significant
differences were detected between intervention groups. Although
we attempted to validate all reported abstinence, we managed
to achieve this in just over half of those who claimed to have
stopped smoking at six months. Using validated rather than
reported outcomes, quit rates still did not differ between
participants offered differing levels of support; however, offering
nicotine replacement therapy became significantly less likely
to promote validated smoking cessation. Participants who were
offered nicotine replacement therapy had the lowest rates of
biochemical validation of smoking status and it is possible that
non-smokers in this group were more reluctant to permit their
smoking status to be verified. Overall, it seems likely that the
principal findings of the study are valid, and offering either
proactive support or no cost nicotine replacement therapy in
addition to standard quitline care was not effective for smoking
cessation.
Comparison with other studies
It seems counterintuitive that offering nicotine replacement
therapy through a helpline is not more effective than usual
quitline care and this is the opposite to what was found in the
only previous trial to test this question.15 This study was done
in the United States in which smoking cessation drug therapies
and behavioural support are not readily available to all smokers.
In England such interventions are freely available through the
NHS, and established standard quitline practice involved
advising all callers (including trial participants) how to access
these. Table 5 suggests that participants who were not offered
nicotine replacement therapy vouchers made more use of
non-trial cessation interventions than those who were offered
such therapy. This greater use of evidence based interventions
by participants not offered nicotine replacement therapy may
have offset any difference that might have arisen owing to the
provision of free nicotine replacement therapy to the other group.
Participants allocated to receive standard or more proactive
support reported similar uptake of smoking cessation
interventions from non-quitline sources, so differential use of
such effective interventions does not seem to explain the similar
outcomes in these two groups. A previous UK trial found
proactive telephone support through a helpline to be ineffective
and the authors argued that proactive counselling had probably
not been delivered as intended because the protocol for offering
this support was non-structured and client led.25 In our trial we
provided quitline staff with substantial training in proactive
counselling, and staff followed a structured protocol for
delivering proactive calls that was integrated into the clinical
information system used to guide cessation care. Calls to
participants were controlled by an automated system rather than
by quitline advisors themselves. This organisation of calling by
the quitline therefore makes it highly unlikely that advisors did
not contact participants as intended. However, participants in
the proactive support and routine support groups still received
similar numbers of completed telephone calls, and far fewer
calls were made to those offered extra proactive support than
would have been if participants had generally accepted all
offered. This similarity between interventions delivered in the
standard support andmore proactive trial arms probably explains
the similarity in outcomes achieved. Why less completed,
successful calls than expected were received by participants
who were offered more intensive support remains unknown.
Difficulties could have been encountered in contacting
participants, but as advisors arranged mutually convenient call
times with smokers, this inability to successful complete calls
probably reflects a lack of enthusiasm for repeated telephone
counselling among participants. A reticence to engage with
repeated telephone counselling has also been observed among
callers to the NewYork State quitline as, in a recent trial, callers
randomised to an offer of either two or four telephone
counselling sessions, completed similar numbers of calls.26
Conclusions and policy implications
In England, where support for smoking cessation is available
to all smokers either free or at relatively low cost, adding
additional proactive telephone counselling or an offer of free
nicotine replacement therapy to usual quitline care did not affect
smoking cessation rates. On the basis of this study, providing
these through a quitline is not recommended.
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What is already known on this topic
Quitlines can support large numbers of smokers in achieving smoking cessation
The most effective and cost effective methods of support through quitlines need to be determined
What this study adds
Among callers who sought help to stop smoking through the English quitline, offering free nicotine replacement therapy was no more
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Cessation rates were not improved by offering additional telephone contacts with advisors providing proactive counselling
Offering free nicotine replacement therapy or proactive support were no more effective than standard reactive quitline support
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Tables
Table 1| Completeness of telephone follow-up and smoking outcomes in two intervention groups. Values are numbers (percentages) unless
stated otherwise
Nicotine replacement therapyLevel of support
Total (n=2591)Follow-up Offered (n=1295)Not offered (n=1296)Proactive (n=1296)Standard (n=1295)
Telephone follow-up:
842 (65.0)851 (65.7)809 (62.4)884 (68.3)1693 (65.3)At one month
670 (51.7)684 (52.8)668 (51.5)686 (53.0)1354 (52.3)At six months
670 (57.8)684 (58.2)668 (57.2)686 (58.8)1354/2334 (58.0)At six months (as % of contactable
participants)*
Questionnaire responses:
4150434891No returned†
711 (54.9)734 (56.6)711 (54.9)734 (56.7)1445 (55.8)Complete six month follow-up‡
229 (17.7)261 (20.1)236 (18.2)254 (19.6)490 (18.9)Self reported smoking cessation at six
months§
Validation of self reported non-smokers at
six months (n=490):
108/229¶ (47.2)147/261¶ (56.3)123/236¶ (52.1)132/254¶ (52.0)255 (52.0)Self reported smokers providing carbon
monoxide sample
85/1295 (6.6)122/1296 (9.4)100/1296 (7.7)107/1295 (8.3)207/2591 (8.0)Validated smoking cessation by treatment
group
Agreement between carbon monoxide
validation and self report for participants with
sample (n=255):
85/108 (78.7)122/147 (82.9)100/123 (81.3)107/132 (81.1)207/255 (81.2)Abstinence confirmed by carbon monoxide
reading
*Telephone lines still working.
†Responses by participants not contactable by telephone.
‡Total of telephone and questionnaire responses.
§Includes 21 who reported being non-smokers on questionnaire responses and for whom no attempt was made at validation.
¶Denominator is number of self reported smokers in each intervention group.
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Table 2| Comparison of baseline characteristics by treatment group. Values are numbers (percentages) unless stated otherwise
Total (n=2591)
Nicotine replacement therapyLevel of support
Characteristics Not offered (n=1295)Offered (n=1296)Proactive (n=1296)Standard (n=1295)
1137 (43.9)543 (41.9)594 (45.9)569 (43.9)568 (43.9)Men
1355 (52.3)706 (54.6)649 (50.0)677 (52.3)678 (52.3)Women
99 (3.8)46 (3.5)53 (4.1)50 (3.8)49 (3.8)Missing
38 (28-50)37 (28-49)38 (28-50)38 (28-49)38 (27-50)Median (interquartile range) age (years)
12257656260Missing
Ethnicity:
2281 (88.1)1142 (88.2)1139 (87.9)1145 (88.3)1136 (87.7)White
96 (3.7)45 (3.5)51 (3.9)42 (3.2)54 (4.2)African* or mixed
99 (3.8)48 (3.7)51 (3.9)49 (3.9)50 (3.9)Asian† or mixed
32 (1.2)22 (1.7)10 (0.8)15 (1.1)17 (1.3)Other
83 (3.2)38 (2.9)45 (3.5)45 (3.5)38 (2.9)Missing
Age left education:
109 (4.2)49 (3.8)60 (4.6)53 (4.1)56 (4.3)Not yet finished
77 (2.9)45 (3.5)32 (2.5)45 (3.5)32 (2.5)≤14
413 (15.9)201 (15.5)212 (16.3)195 (15.0)218 (16.8)15
890 (34.4)456 (35.3)434 (33.5)434 (33.5)456 (35.2)16
222 (8.6)112 (8.6)110 (8.5)115 (8.9)107 (8.3)17
313 (12.2)160 (12.3)153 (11.8)172 (13.3)141 (10.9)18
496 (19.1)239 (18.5)257 (19.9)244 (18.8)252 (19.5)≥19
71 (2.7)33 (2.5)38 (2.9)38 (2.9)33 (2.5)Missing
Index of multiple deprivation score:
23.08 (1.5-78.4)23.4 (1.5-77.5)22.7 (1.73-78.4)23.4 (1.57-78.4)22.7 (1.5-78.4)Median (range)
26.7 (16.5)27.2 (16.7)26.1 (16.3)26.9 (16.5)26.4 (16.6)Mean (SD)
5625313224Missing
Heaviness of smoking index:
773 (29.8)389 (30.0)384 (29.6)376 (29.0)397 (30.6)0-2 (light)
1199 (46.3)598 (46.2)601 (46.4)603 (46.5)596 (46.0)3-4 (moderate)
539 (20.8)269 (20.8)270 (20.8)270 (20.8)269 (20.8)5-6 (heavy)
80 (3.1)39 (3.0)41 (3.2)47 (3.6)33 (2.5)Missing
Average cigarettes per day:
497 (19.2)230 (17.8)267 (20.6)245 (18.9)252 (19.4)≤10
1226 (47.3)629 (48.6)597 (46.1)623 (48.1)603 (46.7)11-20
547 (21.1)290 22.4)257 (19.8)263 (20.3)284 (21.9)21-30
230 (8.9)103 (7.9)127 (9.8)117 (9.1)113 (8.8)≥31
26 (1.0)13 (1.0)13 (1.0)12 (0.9)14 (1.0)Other tobacco
65 (2.5)30 (2.3)35 (2.7)36 (2.7)29 (2.2)Missing
Time to first cigarette on waking:
1012 (39.1)492 (38.0)520 (40.2)493 (38.0)519 (40.0)<5 minutes
825 (31.8)422 (32.7)403 (31.0)426 (32.9)399 (30.8)5 minutes to 1 hour
381 (14.8)195 (15.0)186 (14.3)178 (13.8)203 (15.8)0.5 to 1 hour
294 (11.3)148 (11.4)146 (11.3)153 (11.8)141 (10.9)>1 hour
79 (3.0)38 (2.9)41 (3.2)46 (3.5)33 (2.5)Missing
Urges to smoke in past 24 hours:
97 (3.7)44 (3.4)53 (4.1)49 (3.8)48 (3.7)Not at all
340 (13.1)168 (12.9)172 (13.3)179 13.8)161 (12.4)A little of the time
825 (31.9)416 (32.2)409 (31.5)411 (31.8)414 (32.0)Some of the time
770 (29.7)393 (30.3)377 (29.2)386 (29.8)384 (29.6)A lot of the time
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Table 2 (continued)
Total (n=2591)
Nicotine replacement therapyLevel of support
Characteristics Not offered (n=1295)Offered (n=1296)Proactive (n=1296)Standard (n=1295)
304 (11.7)152 (11.8)152 (11.7)153 (11.8)151 (11.8)Almost all of the time
148 (5.8)66 (5.1)82 (6.3)66 (5.1)82 (6.3)All the time
31 (1.2)21 (1.6)10 (0.7)10 (0.7)21 (1.6)Don’t know
76 (2.9)35 (2.7)41 (3.2)42 (3.2)34 (2.6)Missing
Quit attempts lasting >24 hours in past 12
months:
1091 (42.1)542 (41.8)549 (42.4)559 (43.1)532 (41.1)Yes
1430 (55.2)721 (55.7)709 (54.7)698 (53.9)732 (56.5)No
70 (2.7)32 (2.5)38 (2.9)39 (3.0)31 (2.4)Missing
Other smokers in household:
923 (35.7)472 (36.5)451 (34.8)447 (34.5)476 (36.7)Yes
1602 (61.8)793 (61.2)809 (62.5)813 (62.8)789 (60.9)No
66 (2.5)30 (2.3)36 (2.7)36 (2.7)30 (2.4)Missing
Previous smoking support‡:
498 (19.2)255 (19.7)261 (20.4)240 (18.5)276 (21.3)Nicotine replacement therapy without
prescription
479 (18.5)64 (4.9)59 (4.5)64 (4.9)59 (4.5)Nicotine replacement therapy from health
professional
37 (1.4)15 (1.1)12 (0.9)18 (1.4)9 (0.6)Bupropion
165 (6.3)30 (2.3)30 (2.3)37 (2.8)23 (1.7)Varenicline
125 (4.8)7 (0.5)14 (1.1)9 (0.7)12 (0.9)NHS Stop Smoking Service
221 (8.5)0000NHS 1 to 1
40 (1.5)1 (<0.1)1 (< 0.1)1 (<0.1)1 (<0.1)Other quitline
114 (4.4)14 (1.1)16 (1.2)19 (1.5)11 (0.8)Other
*Including Caribbean.
†Including Indian subcontinent and China.
‡Percentages may total more than 100 as participants could select more than one mode of support.
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Table 3| Smoking cessation outcomes in standard andmore intensive, proactive support groups. Values are numbers (percentages) unless
stated otherwise
P value
Adjusted odds
ratio* (95% CI)
P value
Unadjusted odds
ratio (95% CI)
Level of support
Total (n=2591)Outcomes at follow-up
Proactive
(n=1296)Standard (n=1295)
Six months:
0.460.92 (0.75 to 1.14)0.360.91 (0.75 to 1.11)236 (18.2)254 (19.6)490 (18.9)Prolonged cessation†
0.840.97 (0.72 to 1.30)0.610.93 (0.70 to 1.23)100 (7.7)107 (8.3)207 (8.0)Carbon monoxide validated
cessation
0.600.95 (0.77 to 1.16)0.520.94 (0.78 to 1.14)259 (20.0)272 (21.0)531 (20.5)Self reported cessation for ≥7
days
0.850.97 (0.72 to 1.31)0.550.92 (0.69 to 1.22)96 (7.4)104 (8.0)200 (7.7)Carbon monoxide validated
cessation for ≥7 days
0.951.01 (0.80 to 1.26)0.860.98 (0.79 to 1.21)199 (15.3)202 (15.6)401 (15.5)Reported cessation for ≥3
months
0.681.04 (0.86 to 1.26)0.861.02 (0.85 to 1.22)299 (23.1)295 (22.8)594 (22.9)Reported ≥1 quit attempts
lasting >24 hours‡
————2 (1-3)2 (1-4)2 (1-4)Median (interquartile range)
No of quit attempts reported
One month:
0.550.95 (0.80 to 1.12)0.350.93 (0.79 to 1.09)507 (39.1)533 (41.1)1040 (40.1)Prolonged cessation since quit
date
0.180.88 (0.75 to 1.06)0.070.85 (0.73 to 1.01)393 (30.3)438 (33.8)831 (32.0)Reported cessation for ≥7
days
*Adjusted for age, sex, educational level, and heaviness of smoking index; 2397 cases included in adjusted analyses.
†Primary outcome (includes questionnaire data).
‡In addition to attempt made on quit date for trial.
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Table 4| Smoking cessation outcomes in relation to nicotine replacement therapy. Values are numbers (percentages) unless stated otherwise
P value
Adjusted odds
ratio* (95% CI)
P value
Unadjusted odds
ratio (95% CI)
Nicotine replacement therapy
Total (n=2591)Outcomes at follow-up Offered (n=1295)
Not offered
(n=1296)
Six months:
0.160.86 (0.70 to 1.06)0.110.85 (0.70 to 1.04)229 (17.7)261 (20.1)490 (18.9)Prolonged cessation†
0.0050.65 (0.48 to 0.88)0.0080.67 (0.50 to 0.90)85 (6.6)122 (9.4)207 (8.0)Carbon monoxide validated
prolonged cessation
0.130.85 (0.70 to 1.04)0.090.85 (0.70 to 1.03)248 (19.1)283 (21.8)531 (20.5)Self reported cessation for ≥7
days
0.0040.64 (0.47 to 0.87)0.0060.66 (0.49 to .88)81 (6.2)119 (9.2)200 (7.7)Carbon monoxide validated
cessation for ≥7 days
0.140.84 (0.67 to 1.05)0.090.83 (0.67 to 1.03)185 (14.3)216 (16.6)401 (15.5)Reported cessation for ≥3
months
0.601.05 (0.87 to 1.27)0.451.07 (0.89 to 1.29)305 (23.5)289 (22.3)594 (22.9)Reported ≥1 quit attempts
lasting >24 hours‡
————2 (1-3)2 (1-4)2 (1-4)Median (interquartile range)
No of quit attempts reported
One month:
0.881.01 (0.86 to 1.19)0.930.99 (.85 to 1.16)520 (40.1)520 (40.1)1040 (40.1)Prolonged cessation since quit
date
0.970.99 (0.84 to 1.18)0.850.98 (.83 to 1.16)417 (32.2)414 (31.9)831 (32.0)Reported cessation for ≥7
days
*Adjusted for age, sex, educational level, and heaviness of smoking index; 2397 cases included in adjusted analyses.
†Primary outcome (includes questionnaire data).
‡In addition to attempt made on quit date for trial.
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Table 5| Participants’ reported use of trial and non-trial smoking cessation support and successful telephone contacts. Values are numbers
(percentages) unless stated otherwise
Nicotine replacement therapyLevel of support*Reported use of support, and telephone contacts
Offered (n=1295)Not offered (n=1296)Proactive (n=1296)Standard (n=1295)
Trial nicotine replacement therapy:
555§ (42.9)—263 (20.3)292 (22.5)Received any
285 (51.3)—135 (51.3)150 (51.4)Used every day
133 (23.9)—63 (23.9)70 (24.0)Used most days
45 (8.1)—22 (8.4)23 (7.9)Used once or twice weekly
37 (6.7)—13 (4.9)24 (8.2)Used less than once weekly
36 (6.5)—20 (7.6)16 (5.5)No use since quit date
19 (3.4)—10 (3.8)9 (3.1)Could not remember
Non-trial support†:
276 (21.3)222 (17.1)251 (19.4)247 (19.1)Nicotine replacement therapy without prescription
225 (17.4)254 (19.6)238 (18.4)241 (18.6)Nicotine replacement therapy from health
professional
20 (1.5)17 (1.3)17 (1.3)20 (1.5)Bupropion
64 (4.9)101 (7.8)77 (5.9)88 (6.8)Varenicline
53 (4.1)72 (5.6)58 (4.5)67 (5.2)NHS Stop Smoking Service
103 (8.0)118 (9.1)112 (8.6)109 (8.4)NHS 1 to 1
20 (1.5)20 (1.5)13 (1.0)27 (2.1)Other quitline
57 (4.4)57 (4.4)51 (3.9)63 (4.9)Other
193 (14.9)183 (14.1)178 (13.7)198 (15.3)None of these
Successful telephone contacts:
1062107210811053‡No of participants receiving outbound calls
2.89 (1.75)2.92 (1.78)3.35 (1.97)2.44 (1.38)Mean (SD) No of calls participants received§
3 (1-4)3 (1-4)3 (1-5)2 (1-3)Median (interquartile range) No of calls participants
received
51525350No of participants contacting quitline for support
1.06 (0.24)1.07 (0.33)1.04 (0.19)1.1 (0.36)Mean (SD) No of calls from participants
1 (1-1)1 (1-1)1 (1-1)1 (1-1)Median (interquartile range) No of calls from
participants
*648 in both groups were also offered nicotine replacement therapy.
†Percentages may total more than 100 as participants could select more than one mode of support.
‡242 (1295−1053) received no successful calls.
§Indicates that 70.0% of participants (555/798) redeemed their voucher for nicotine replacement therapy.
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Figure
Participant flow within treatment groups
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